Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure

P Armand, MA Shipp, V Ribrag, JM Michot… - Journal of Clinical …, 2016 - ascopubs.org
Purpose Classical Hodgkin lymphoma (HL) frequently exhibits genetic alterations leading to
overexpression of the programmed death-1 (PD-1) ligands, suggesting a possible …
被引用次数：709 相关文章

Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure

P Armand, MA Shipp, V Ribrag, JM Michot… - Journal of Clinical …, 2016 - cir.nii.ac.jp
Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin
Lymphoma After Brentuximab Vedotin Failure | CiNii Research CiNii 国立情報学研究所 学術 …

Programmed death-1 blockade with pembrolizumab in patients with classical hodgkin lymphoma after brentuximab vedotin failure

P Armand, MA Shipp, V Ribrag, JM Michot… - JOURNAL OF …, 2016 - cris.unibo.it
Abstract Purpos Classical Hodgkin lymphoma (HL) frequently exhibits genetic alterations
leading to overexpressio of the programmed death-1 (PD-1) ligands, suggesting a possible …
[PDF] dana-farber.org

[PDF][PDF] Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure

P Armand, MA Shipp, V Ribrag, JM Michot… - …, 2014 - shipplab.dana-farber.org
Purpose Classical Hodgkin lymphoma (HL) frequently exhibits genetic alterations leading to
overexpression of the programmed death-1 (PD-1) ligands, suggesting a possible …

Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure.

P Armand, MA Shipp, V Ribrag, JM Michot… - Journal of Clinical …, 2016 - europepmc.org
Purpose Classical Hodgkin lymphoma (HL) frequently exhibits genetic alterations leading to
overexpression of the programmed death-1 (PD-1) ligands, suggesting a possible …

Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure

P Armand, MA Shipp, V Ribrag… - Journal of clinical …, 2016 - pubmed.ncbi.nlm.nih.gov
Purpose Classical Hodgkin lymphoma (HL) frequently exhibits genetic alterations leading to
overexpression of the programmed death-1 (PD-1) ligands, suggesting a possible …
[HTML] miami.edu

[HTML][HTML] Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure

P Armand, MA Shipp, V Ribrag… - Journal of clinical …, 2016 - scholarship.miami.edu
Abstract Adult Aged Antibodies, Monoclonal, Humanized-adverse effects Antibodies,
Monoclonal, Humanized-therapeutic use Antineoplastic Agents, Immunological-adverse …
[HTML] nih.gov

[HTML][HTML] Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure

P Armand, MA Shipp, V Ribrag, JM Michot… - Journal of Clinical …, 2016 - ncbi.nlm.nih.gov
Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin
Lymphoma After Brentuximab Vedotin Failure - PMC Back to Top Skip to main content NIH …

Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure.

P Armand, MA Shipp, V Ribrag, JM Michot… - Journal of Clinical …, 2016 - europepmc.org
Purpose Classical Hodgkin lymphoma (HL) frequently exhibits genetic alterations leading to
overexpression of the programmed death-1 (PD-1) ligands, suggesting a possible …